Medline director granted 5,387 RSUs in stock awards

Medline Inc. director Todd M. Bluedorn reported stock-based compensation awards rather than open-market trades.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Medline Inc. director Todd M. Bluedorn reported stock-based compensation awards rather than open-market trades. He received 5,387 shares of Class A Common Stock on June 11, 2026 as a grant of restricted stock units (RSUs) that vest on the earlier of the first anniversary of grant or the next annual stockholder meeting. An earlier RSU grant of 10,345 shares on December 16, 2025 is also shown, vesting on March 30, 2027. Following the most recent award, he directly holds 15,732 shares of Medline Class A Common Stock, all acquired through grants.

Insider Trade Summary

Grant/Award: 15,732 shares

Grant/Award 2 txns

Insider Bluedorn Todd M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	5,387	$0.00	$0.00
Grant/Award	Class A Common Stock	10,345	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 15,732 shares (Direct)

Footnotes (2)

F1. Represents a grant of restricted stock units ("RSUs") that vest on March 30, 2027. These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.
F2. Represents a grant of RSUs that vest on the earlier of (i) the first anniversary of the date of grant, and (ii) the next annual meeting of stockholders following the date of grant.

Key Figures

Latest RSU grant: 5,387 shares Prior RSU grant: 10,345 shares Holdings after grant: 15,732 shares +3 more

6 metrics

Latest RSU grant 5,387 shares Class A Common Stock RSUs granted June 11, 2026

Prior RSU grant 10,345 shares Class A Common Stock RSUs granted December 16, 2025

Holdings after grant 15,732 shares Direct Class A Common Stock following June 11, 2026 award

Grant price $0.00 per share Indicates compensation grants, not cash purchases

2027 vesting date March 30, 2027 Vesting date for 10,345 RSUs granted December 16, 2025

Annual-meeting vesting trigger Earlier of 1 year or next annual meeting Vesting condition for 5,387 RSUs granted June 11, 2026

Key Terms

restricted stock units ("RSUs"), Form 3, annual meeting of stockholders, Class A Common Stock

4 terms

restricted stock units ("RSUs") financial

"Represents a grant of restricted stock units ("RSUs") that vest on March 30, 2027."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Form 3 regulatory

"These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

annual meeting of stockholders regulatory

"vest on the earlier of (i) the first anniversary of the date of grant, and (ii) the next annual meeting of stockholders following the date of grant."

Class A Common Stock financial

"security_title": "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medline (MDLN) director Todd M. Bluedorn report?

Todd M. Bluedorn reported receiving stock-based compensation awards, not open-market trades. He acquired 5,387 shares of Medline Class A Common Stock as restricted stock units on June 11, 2026, bringing his direct holdings to 15,732 shares after the grant.

How many Medline (MDLN) shares does Todd M. Bluedorn now hold after the Form 4 filing?

After the latest grant, Todd M. Bluedorn directly holds 15,732 shares of Medline Class A Common Stock. These holdings come from restricted stock unit awards granted as director compensation, rather than from open-market purchases of the company’s stock.

What were the terms of Todd M. Bluedorn’s June 11, 2026 RSU grant at Medline (MDLN)?

On June 11, 2026, Bluedorn received 5,387 restricted stock units in Medline Class A Common Stock. These RSUs vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant date.

What earlier RSU award to Todd M. Bluedorn in Medline (MDLN) is disclosed?

The filing also shows a grant of 10,345 restricted stock units on December 16, 2025. According to the disclosure, these RSUs vest on March 30, 2027 and were previously reported on Bluedorn’s Form 3 filed on December 17, 2025.

Were Todd M. Bluedorn’s Medline (MDLN) transactions open-market buys or compensation grants?

The transactions are classified as grants or awards, not open-market purchases. Both entries show acquisition code “A” with a zero price per share, indicating stock-based compensation in the form of restricted stock units rather than cash-funded share purchases.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/15/2026 - 05:50 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bluedorn Todd M

(Last)

(First)

(Middle)

C/O MEDLINE INC.

3 LAKES DRIVE

(Street)

NORTHFIELD

ILLINOIS

60093

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medline Inc. [ MDLN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	12/16/2025		A⁽¹⁾		10,345	A	$0	10,345	D
Class A Common Stock	06/11/2026		A⁽²⁾		5,387	A	$0	15,732	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") that vest on March 30, 2027. These securities were previously reported on the Reporting Person's Form 3 filed on December 17, 2025.

2. Represents a grant of RSUs that vest on the earlier of (i) the first anniversary of the date of grant, and (ii) the next annual meeting of stockholders following the date of grant.

	/s/ Nicole Fritz, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR